{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:05:52Z","timestamp":1789661152249,"version":"4.0.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Tianjin Health Science and Technology Project","award":["TJWJ2022MS005"],"award-info":[{"award-number":["TJWJ2022MS005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-04784-6","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:35:24Z","timestamp":1770028524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of semaglutide in IgA nephropathy with obesity: a case report"],"prefix":"10.1186","volume":"27","author":[{"given":"Hongfen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenya","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"1","key":"4784_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1056\/NEJM200301023480117","volume":"348","author":"EN Wardle","year":"2003","unstructured":"Wardle EN. IgA nephropathy [J]. N Engl J Med. 2003;348(1):79\u201381. author reply 79\u201381.","journal-title":"N Engl J Med"},{"issue":"2","key":"4784_CR2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.23876\/j.krcp.22.001","volume":"41","author":"JH Yu","year":"2022","unstructured":"Yu JH, Park SY, Lee DY, et al. GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions [J]. Kidney Res Clin Pract. 2022;41(2):136\u201349.","journal-title":"Kidney Res Clin Pract"},{"issue":"1","key":"4784_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","volume":"31","author":"EM Apperloo","year":"2025","unstructured":"Apperloo EM, Gorriz JL, Soler MJ, et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial [J]. Nat Med. 2025;31(1):278\u201385.","journal-title":"Nat Med"},{"issue":"4","key":"4784_CR4","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2337\/dc22-1889","volume":"46","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Apperloo E, Davies M, et al. Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 trials [J]. Diabetes Care. 2023;46(4):801\u201310.","journal-title":"Diabetes Care"},{"issue":"1","key":"4784_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000492237","volume":"149","author":"L Liu","year":"2025","unstructured":"Liu L, Liu Y, Li J, et al. Efficacy and safety of telitacicept in IgA nephropathy: a retrospective, multicenter study [J]. Nephron. 2025;149(1):1\u201310.","journal-title":"Nephron"},{"issue":"5","key":"4784_CR6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00281-021-00888-3","volume":"43","author":"J Floege","year":"2021","unstructured":"Floege J, Rauen T, Tang SCW. Current treatment of IgA nephropathy [J]. Semin Immunopathol. 2021;43(5):717\u201328.","journal-title":"Semin Immunopathol"},{"issue":"4","key":"4784_CR7","doi-asserted-by":"publisher","first-page":"e098688","DOI":"10.1136\/bmjopen-2024-098688","volume":"15","author":"B Yan","year":"2025","unstructured":"Yan B, Tie X, Wang L, et al. Enteric-coated mycophenolate sodium plus hydroxychloroquine therapy versus hydroxychloroquine for the remission of proteinuria in IgA nephropathy (EMSAR-IgAN trial): study protocol for a randomised trial [J]. BMJ Open. 2025;15(4):e098688.","journal-title":"BMJ Open"},{"key":"4784_CR8","doi-asserted-by":"crossref","unstructured":"Ss K. V P. Effects of semaglutide on CKD in patients with type 2 diabetes [J]. Kidney Int Rep. 2024;10(2).","DOI":"10.1016\/j.ekir.2024.11.1365"},{"key":"4784_CR9","doi-asserted-by":"publisher","first-page":"100340","DOI":"10.1016\/j.jcte.2024.100340","volume":"36","author":"H Yaribeygi","year":"2024","unstructured":"Yaribeygi H, Maleki M, Jamialahmadi T, et al. Anti-inflammatory benefits of semaglutide: state of the art [J]. J Clin Translational Endocrinol. 2024;36:100340.","journal-title":"J Clin Translational Endocrinol"},{"key":"4784_CR10","doi-asserted-by":"crossref","unstructured":"Si FL, Tang C, Chen P, et al. Effectiveness of semaglutide in overweight or obese patients with IgA nephropathy without diabetes [J]. Nephrology (Carlton, Vic.). 2025;30(4):e70023.","DOI":"10.1111\/nep.70023"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04784-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04784-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04784-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:04:16Z","timestamp":1772582656000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04784-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4784"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04784-6","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"27 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This paper abides by the declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}